



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

13 February 2006

Mr. Milo Stanojevich
Country Director
CARE Peru
Av. Gral. Santa Cruz 659
Jesus Maria 659
Lima - Peru

**Subject: Program Grant Agreement Number PER-202-G01-H-00
Implementation Letter Number 5**

Dear Mr. Stanojevich,

We refer to the Program Grant Agreement between The Global Fund to Fight AIDS, Tuberculosis and Malaria (the "Global Fund") and CARE Peru (the "Principal Recipient") for an HIV/AIDS program entitled "Strengthening Prevention and Control of AIDS in Peru", effective 4 November 2003 and amended by letters dated 15 July 2004, 28 April 2005, 22 June 2005 and 30 November 2005 (as amended from time to time, the "Grant Agreement"). Capitalized terms used but not defined in this letter have the meaning given to them in the Grant Agreement.

As you know, the Global Fund has decided to continue funding the Program for the remaining years ("Phase 2") of the Program. We are currently negotiating the documents necessary to negotiate the Phase 2 renewal.

As you are aware, the Program Ending Date of the Grant Agreement is 31 January 2006. In order to ensure that Program activities are not disrupted during our negotiation of the Phase 2 renewal documents, the Global Fund proposes to amend the Grant Agreement by extending the Program Ending Date to 31 May 2006. Please note that this amendment is an interim measure to avoid disruption to the Program activities and that Phase 2 will be deemed to have begun on 1 December 2005.

We have also taken this opportunity to update the Global Fund's Additional Representative.

By signing this implementation letter, the Global Fund and the Principal Recipient agree to amend blocks 3A, 5 and 13 of the face sheet of the Grant Agreement as follows:

Block 3A: Modification Number and Date: Modification 05, 13 February 2006

Block 5: Program Ending Date: May 31, 2006

Block 13: Global Fund Additional Representative:
Helen Evans
Deputy Executive Director and Interim Chief of Operations
Chemin de Blandonnet, 8
1214 Vernier
Geneva, Switzerland
Tel.: +41-22-791-1700 Fax: +41-22-791-1701

Page 1 of 2

During the period 1 December 2005 to 31 May 2006 (the "Extension Period"), the Principal Recipient shall continue to conduct Program activities in line with the activities conducted to date and shall report on the indicators in the attached table ("Indicators & Targets for First and Second Quarters of Year Three").

Achievement of the targets for the Extension Period, in addition to other relevant information, shall be used by the Global Fund as a basis for determining disbursements of Grant funds. Disbursement of Grant funds will only be made against submission of a budget for the Extension Period that is acceptable to the Global Fund.

Except as modified herein, the Grant Agreement remains in full force and effect.

This amendment shall come into force on the date of signature of this letter by both parties. Please confirm your agreement with the foregoing by signing both enclosed copies of this letter and returning one to us, retaining one copy for your records.

We thank you and your partners for undertaking this important effort in the global fight against HIV/AIDS.

Yours sincerely

Helen Evans
Deputy Executive Director and Interim Chief of Operations

Agreed and Signed:

For: CARE Peru

By: _____
Authorized Representative: Milo Stanojevich – Country Director

Date: 16 - 02 - 2006

cc: Dr. Pilar Mazzetti Soler, Chairperson, Country Coordinating Mechanism
Mr. Ernesto Leyva F. / Mr. Oscar la Torre, Local Fund Agent, PricewaterhouseCoopers

Attachment: Amended face sheet of the Grant Agreement
Table: "Indicators & Targets for First and Second Quarters of Year Three"

Indicators & Targets for First Quarter of Year Three

Program Details

Country:	PERU
Disease:	HIV/AIDS
Grant number:	PER-202-GO1-H-00
Principal Recipient:	CARE PERU

Program Objectives over Phase 1										
Objective Number	Objective Description									
1	Main program objective 1: Encouraging healthy lifestyles among adolescents and young people with regard to STI/HIV/AIDS									
2	Main program objective 2: Reducing the prevalence of HIV/AIDS in vulnerable populations									
3	Main program objective 3: Reducing vertical HIV transmission									
4	Main program objective 4: Ensuring quality integral care for PLWHA, including access to antiretroviral treatment									
6	Main program objective 6: Strengthening the response of civil society and the State to the HIV/AIDS epidemic									
Objective Number	Service Delivery Area	Coverage Indicator description	Indicator in Spanish	Indicator level	Direct/ Ind (Y/N)	Baseline (if applicable)*			Targets for Year 3 Q1 & Q2 (additional targets, not cumulative from Year 2)	
						Value	Year	Source	Q1	Q2
2	Programme for specific groups	% of MSM estimated to make use of periodic medical attention (*)	% de HSH abordables que acuden a Atención Médica Periódica	3	N	42,4%	2003	MOH Information system - ESN VIH	62%	62%
2	Programme for specific groups	% of CSW estimated to make use of periodic medical attention (*)	% de TS que acuden a Atención Médica Periódica	3	N	57,7%	2003	MOH Information system - ESN VIH	29%	45%
3	Prevention of Mother to Child Transmission (PMTCT)	Number and percentage of seropositive pregnant women without prenatal checks who receive antiretroviral prophylaxis during birth in hospital	Número y % de gestantes seropositivas sin control pre-natal que reciben profilaxis con antirretrovirales al momento del parto institucionalizado	3	N	0	2003	MOH Information system	20 10%	60 30%
3	Prevention of Mother to Child Transmission (PMTCT)	% of pregnant women who receive HIV rapid tests	% de gestantes sin control prenatal tamizadas con pruebas rápidas en el momento del parto	3	N	0	2003	MOH Information system	10,000 7%	35,000 25%
3	Prevention of Mother to Child Transmission (PMTCT)	Number and % of pregnant women who receive counselling and testing for HIV	Número y % de gestantes que se realizan consejería y pruebas de tamizaje para VIH	3	N	38,90%	2003	MOH Information system	60,000 10%	180,000 30%
4	Antiretroviral treatment (ART) and monitoring	Number and percentage of people living with HIV in immune-deficiency stage receiving antiretrovirals (ARVs) according MOH technical regulations	Número y % de personas viviendo con VIH en fase de inmunodeficiencia que reciben antirretrovirales	3	N	2158 25%	2003	MOH Information system	7000 (Cumulative target from Year 2) 61,25%	7400 64,75%
4	Antiretroviral treatment (ART) and monitoring	Percentage of adherence to ARV treatment	% de adherencia al tratamiento antirretroviral	3	N	0	2003	MOH Information system	80%	80%
4	Antiretroviral treatment (ART) and monitoring	Number of PLWHA receiving tests for monitoring viral load and CD4 lymphocytes	Número de personas viviendo con VIH que reciben pruebas de monitoreo de la carga viral y CD4	3	N	25%	2003	MOH Information system	6075 (Cumulative target from Year 2)	6615
4	Care and support	Number of PLWHIV in ARV programme who receive counselling by peer counselors	Numero de PVVS en carga que reciben consejería por los CEPS	3	N	960	2005	Programme monitoring system	960	1008